Bardakci Fevzi, Kusat Kevser, Adnan Mohd, Badraoui Riadh, Alam Mohammad Jahoor, Alreshidi Mousa M, Siddiqui Arif Jamal, Sachidanandan Manojkumar, Akgöl Sinan
Department of Biology, College of Science, University of Hail, Hail P.O. Box 2440, Saudi Arabia.
Molecular Diagnostics and Personalized Therapeutics Unit, University of Hail, Hail P.O. Box 2440, Saudi Arabia.
Polymers (Basel). 2022 Nov 21;14(22):5038. doi: 10.3390/polym14225038.
In this study, a novel polymeric nanomaterial was synthesized and characterized, and it its potential usability in hypertension treatment was demonstrated. For these purposes, a poly(hydroxyethyl methacrylate-methacryloylamidophenylalanine)-based polymeric nanomaterial (p(HEMPA)) was synthesized using a mini-emulsion polymerization technique. The nanomaterials were characterized using scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR), and zeta size analysis. The synthesized p(HEMPA) nanomaterial had a diameter of about 113 nm. Amlodipine-binding studies were optimized by changing the reaction conditions. Under optimum conditions, amlodipine's maximum adsorption value (Qmax) of the p(HEMPA) nanopolymer was found to be 145.8 mg/g. In vitro controlled drug release rates of amlodipine, bound to the nanopolymer at the optimum conditions, were studied with the dialysis method in a simulated gastrointestinal system with pH values of 1.2, 6.8 and 7.4. It was found that 99.5% of amlodipine loaded on the nanomaterial was released at pH 7.4 and 72 h. Even after 72 h, no difference was observed in the release of AML. It can be said that the synthesized nanomaterial is suitable for oral amlodipine release. In conclusion, the synthesized nanomaterial was studied for the first time in the literature as a drug delivery system for use in the treatment of hypertension. In addition, AML-p(HEMPA) nanomaterials may enable less frequent drug uptake, have higher bioavailability, and allow for prolonged release with minimal side effects.
在本研究中，合成并表征了一种新型聚合物纳米材料，并证明了其在高血压治疗中的潜在可用性。为此，采用微乳液聚合技术合成了一种基于聚（甲基丙烯酸羟乙酯-甲基丙烯酰氨基苯丙氨酸）的聚合物纳米材料（p(HEMPA)）。使用扫描电子显微镜（SEM）、傅里叶变换红外光谱（FTIR）和zeta尺寸分析对纳米材料进行了表征。合成的p(HEMPA)纳米材料直径约为113 nm。通过改变反应条件优化了氨氯地平结合研究。在最佳条件下，p(HEMPA)纳米聚合物对氨氯地平的最大吸附值（Qmax）为145.8 mg/g。在pH值为1.2、6.8和7.4的模拟胃肠系统中，采用透析法研究了在最佳条件下与纳米聚合物结合的氨氯地平的体外控释率。结果发现，负载在纳米材料上的99.5%的氨氯地平在pH 7.4和72 h时释放。即使在72 h后，氨氯地平的释放也没有差异。可以说，合成的纳米材料适用于口服氨氯地平的释放。总之，合成的纳米材料作为一种用于治疗高血压的药物递送系统，在文献中首次进行了研究。此外，AML-p(HEMPA)纳米材料可能使药物摄取频率降低，具有更高的生物利用度，并允许以最小的副作用进行延长释放。
